New therapies, new toxicities
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
Current status and future needs with immunotherapy in triple-negative breast cancer
Recent evidence shows the potential of immunotherapy to change the treatment landscape of triple-negative breast cancer (TNBC), where historically, chemotherapy has been the only systemic option. But, how do we choose what therapy to give which patients?
Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
The ESMO Global Study on Access to Cancer Medicines shows stark global inequalities
The availability and affordability of a broad range of prescription cancer medicines have been analysed
Can telehealth be a genuine replacement for face-to-face healthcare?
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
The effect of ‘publish or perish’ on young academic oncologists
Oncologists at an early stage in their career may fall into the trap of predatory journals whilst seeking to publish their research
Enhanced patient participation in trials may help make cancer research more heterogeneous
In the Patient Advocacy Track, the importance and challenges around placing the patient at the centre of clinical trials